World Journal of Surgery

, Volume 36, Issue 1, pp 192–200 | Cite as

Impact of Preoperative Thrombocytosis on the Survival of Patients with Primary Colorectal Cancer

  • Kazuhito SasakiEmail author
  • Kazushige Kawai
  • Nelson H. Tsuno
  • Eiji Sunami
  • Joji Kitayama



Although thrombocytosis has been reported in patients with various types of cancer, the association between thrombocytosis and the clinicopathological features of patients with colorectal cancer (CRC) has not been fully investigated. We evaluated the clinical features associated with thrombocytosis in CRC.

Materials and methods

The medical records of 636 consecutive CRC patients undergoing surgery in our department between January 2002 and July 2008 were retrospectively reviewed. The correlation between the clinicopathological variables and the preoperative platelet count was analyzed by univariate and multivariate analyses. The impact of thrombocytosis on the prognosis of these patients was assessed, in comparison with the other clinicopathological variables.


Platelet count showed significant correlation with gender, age, venous involvement, tumor size, depth of invasion, regional lymph node metastasis, distant metastasis in univariate analysis, and tumor size and depth of invasion were independent factors in multivariate analysis. The cancer-specific survival (CSS) of CRC patients with thrombocytosis was significantly shorter than that for those without thrombocytosis (P < 0.001), specifically in patients with stage III CRC (P < 0.001). Multivariate analysis indicated that thrombocytosis was an independent prognostic factor of CSS (hazard ratio = 2.96, 95% confidence interval [CI] = 1.72–5.00). Moreover, within stage II CRC, the univariate analysis revealed that disease-free survival (DFS) was associated with preoperative thrombocytosis, but not the other clinicopathological variables.


Preoperative thrombocytosis is not only an independent indicator of poor CSS in CRC patients but also an independent predictor of poor DFS in patients with stage II CRC.


Platelet Count Clinicopathological Variable Thrombocytosis Regional Lymph Node Metastasis Venous Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Xu R, Zhou B, Fung PC et al (2006) Recent advances in the treatment of colon cancer. Histol Histopathol 21:867–872PubMedGoogle Scholar
  2. 2.
    McArdle CS, Hole DJ (2002) Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 86:331–335PubMedCrossRefGoogle Scholar
  3. 3.
    O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRefGoogle Scholar
  4. 4.
    Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026–1038PubMedCrossRefGoogle Scholar
  5. 5.
    McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886PubMedCrossRefGoogle Scholar
  6. 6.
    Jones JM, McGonigle NC, McAnespie M et al (2006) Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53:97–101PubMedCrossRefGoogle Scholar
  7. 7.
    Lee JH, Ryu KW, Kim S et al (2004) Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 51:1860–1863PubMedGoogle Scholar
  8. 8.
    Oya M, Akiyama Y, Okuyama T et al (2001) High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 31:388–394PubMedCrossRefGoogle Scholar
  9. 9.
    Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy, Risk analysis using Medicare claims data. Medicine (Baltimore) 78:285–291CrossRefGoogle Scholar
  10. 10.
    Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9:1826–1830PubMedCrossRefGoogle Scholar
  11. 11.
    Scholz HS, Petru E, Gucer F et al (2000) Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 20:3983–3985PubMedGoogle Scholar
  12. 12.
    Shimada H, Oohira G, Okazumi S et al (2004) Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 198:737–741PubMedCrossRefGoogle Scholar
  13. 13.
    Monreal M, Fernandez-Llamazares J, Pinol M et al (1998) Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost 79:916–918PubMedGoogle Scholar
  14. 14.
    Taucher S, Salat A, Gnant M et al (2003) Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 89:1098–1106PubMedGoogle Scholar
  15. 15.
    Nyasavajjala SM, Runau F, Datta S et al (2010) Is there a role for preoperative thrombocytosis in the management of colorectal cancer? Int J Surg 8:436–438PubMedCrossRefGoogle Scholar
  16. 16.
    Qiu MZ, Yuan ZY, Luo HY et al (2010) Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 31:255–260PubMedCrossRefGoogle Scholar
  17. 17.
    Kandemir EG, Mayadagli A, Karagoz B et al (2005) Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res 33:228–235PubMedGoogle Scholar
  18. 18.
    Amitrano L, Guardascione MA, Brancaccio V et al (2002) Coagulation disorders in liver disease. Semin Liver Dis 22:83–96PubMedCrossRefGoogle Scholar
  19. 19.
    Klinger MH, Jelkmann W (2002) Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22:913–922PubMedCrossRefGoogle Scholar
  20. 20.
    American Joint Cancer Commission (1997) AJCC cancer staging manual. In American Joint Committee on Cancer, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  21. 21.
    Erdemir F, Kilciler M, Bedir S et al (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79:111–116PubMedCrossRefGoogle Scholar
  22. 22.
    Ikeda M, Furukawa H, Imamura H et al (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9:287–291PubMedCrossRefGoogle Scholar
  23. 23.
    Ding PR, An X, Zhang RX et al (2010) Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25:1427–1433PubMedCrossRefGoogle Scholar
  24. 24.
    Benson AB, Choti MA, Cohen AM et al (2000) NCCN practice guidelines for colorectal cancer. Oncology (Williston Park) 14:203–212Google Scholar
  25. 25.
    Benson AB, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRefGoogle Scholar
  26. 26.
    Blay JY, Favrot M, Rossi JF et al (1993) Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 82:2261–2262PubMedGoogle Scholar
  27. 27.
    Verheul HM, Pinedo HM (2003) The importance of platelet counts and their contents in cancer. Clin Cancer Res 9:3219–3221PubMedGoogle Scholar
  28. 28.
    Verheul HM, Hoekman K, Lupu F et al (2000) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6:166–171PubMedGoogle Scholar
  29. 29.
    Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964PubMedCrossRefGoogle Scholar
  30. 30.
    Folman CC, Linthorst GE, van Mourik J et al (2000) Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 83:923–930PubMedGoogle Scholar
  31. 31.
    Jain S, Harris J, Ware J (2010) Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 30:2362–2367PubMedCrossRefGoogle Scholar
  32. 32.
    Janowska-Wieczorek A, Wysoczynski M, Kijowski J et al (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113:752–760PubMedCrossRefGoogle Scholar
  33. 33.
    Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  • Kazuhito Sasaki
    • 1
    Email author
  • Kazushige Kawai
    • 1
  • Nelson H. Tsuno
    • 1
  • Eiji Sunami
    • 1
  • Joji Kitayama
    • 1
  1. 1.Department of Surgical Oncology, Faculty of MedicineThe University of TokyoTokyoJapan

Personalised recommendations